In addition, in the colon, SphK1 regulates the inflammatory cyclooxygenase-2 (COX-2) [139], and elevated COX-2 is both a biomarker for poor patient outcome and a therapeutic target for colon cancers [140,141]. Here, PTGS2 is linked to malignant colon neoplasm.